MATRIX

Developing the next generation of HIV prevention products for women

Kenneth Ngure MPH, PhD
JKUAT/KEMRI/UW
Co-lead D2D Pillar 1
HPTN - Socio-Behavioral and Structural Working Group Member
Presentation Highlights

- MATRIX is supporting early phase R&D for 9 products

- Three phase 1 or 0 studies are nearing implementation in the US, South Africa, Zimbabwe and Kenya
  - MATRIX-001 TAF/EVG insert used vaginally 14 days
  - MATRIX-002 Vaginal 30 day placebo film acceptability study
  - MATRIX-003 Placebo novel dual prevention monthly ring acceptability study

- The Design to Delivery (D2D) Hub Pillar 1 has generated feedback from end-users through design consultations (DCs) and is planning a use of the rapid response network (RRN)

- The Business, Market Dynamics and Commercialization (BACH) hub is supporting the MATRIX PDs through estimating of cost of goods and the feasibility of eventual manufacturing of products in South Africa and Kenya

- The Capacity Strengthening, Engagement and Mentorship (CaSE) mentoring program is providing short and mid term training for approximately 28 scholars and planning in underway for launch of a in depth fellowships for product development
Microbicide Research and Development (R&D) to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence
What is MATRIX?

- A USAID Project to Advance the Research and Development of Innovative HIV Prevention Products for Women – funded in Dec. 2021 for 5 years

- Brings together partner organizations from sub-Saharan Africa and North America, with expertise in *product development, clinical trials, social and behavioral research and market and business case development*

- Led by Sharon Hillier (University of Pittsburgh/ Magee-Womens Research Institute - USA) and Thesla Palanee-Phillips (Wits RHI - South Africa)
Through North-South partnerships, MATRIX goals include development of a range of HIV and pregnancy prevention products that are acceptable, affordable, scalable and deliverable to meet the unmet needs of women at risk of HIV infection and unplanned pregnancy.
How MATRIX is structured

**5 Activity "Hubs"**

**Technology Accelerator**
- Manages development process of products, and with input of an independent Scientific Advisory Group, advises on a product’s next steps
- Provides support to other research and development endeavors through seed funding and other grants, including of projects led by African investigators

**Clinical Trials**
- Oversees design and implementation of placebo studies and Phase 1 trials of products at partner clinical trial sites in the U.S., Kenya, South Africa and Zimbabwe

**Design to Delivery (D2D)**
- Conducts end-user research to understand women’s and stakeholders’ preferences for products and product attributes
- Designs and implements behavioral studies & socio-behavioral research within trials
- Seeks stakeholder feedback on products, proposed studies and regulatory process.

**Business, Market Dynamics and Commercialization (BACH)**
- Conducts business case & market analysis; seeks linkages with possible investors

**Capacity Strengthening, Engagement and Mentorship (CaSE)**
- Matches African investigators with mentorship and fellowship opportunities, with an emphasis on early R&D

**4 Product Developers**
(currently)
- CONRAD/Eastern Virginia Medical School
- Oak Crest Institute of Science
- Population Council
- University of Pittsburgh/Magee-Womens Research Institute
What does the MATRIX product portfolio include?

- A *range* of HIV prevention products to ensure women can have options:
  - Dual-purpose products for prevention of both HIV and pregnancy
  - Products designed to provide protection for six months to a year
  - On-demand vaginal products meant to be used around the time of sex
  - Vaginal products that would be used for a month at a time

- Some are new formulations of existing ARV-based products; others contain novel antiviral agents

- Most have not yet been tested in clinical trials
### Products for Prevention of HIV

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Developer</th>
<th>Product Type</th>
<th>Active Ingredient(s)</th>
<th>How used</th>
<th>Protection Goal</th>
<th>Unique Features/ Additional Information</th>
<th>Development Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAF/EVГ Fast-dissolving vaginal insert</td>
<td>CONRAD (USA)</td>
<td>Fast-dissolving insert</td>
<td>TAF/EVГ tenofovir alafenamide &amp; elvitegravir NRTI &amp; integrase inhibitor (ARVs)</td>
<td>On-demand (women insert themselves at or around time of sex)</td>
<td>Up to 3 days</td>
<td>TAF has also shown activity against HSV, which could be added benefit. CONRAD also evaluating the insert's rectal use.</td>
<td>MATRIX-001 to evaluate the safety and acceptability of insert at sites in Kenya, South Africa &amp; US –the first Phase 1 study in African women. Expected start 2023.</td>
</tr>
<tr>
<td>Griffithsin Fast-dissolving vaginal insert</td>
<td>Population Council (USA)</td>
<td>Fast-dissolving insert</td>
<td>Griffithsin antiviral protein (non-ARV) Viral entry inhibitor</td>
<td>On-demand (women insert themselves at time of sex)</td>
<td>4-8 hours</td>
<td>Animal and laboratory studies indicate Griffithsin also has activity against HPV and HSV, which could be added benefit.</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Dapivirine vaginal film</td>
<td>Univ of Pittsburgh (USA)</td>
<td>Vaginal film</td>
<td>Dapivirine NNRTI (ARV)</td>
<td>Women insert themselves</td>
<td>1 month</td>
<td>Film would slowly release drug until it completely dissolves. Also being developed as dual-purpose product</td>
<td>MATRIX-002 to evaluate acceptability and usability of 2 placebo films at sites in Kenya, South Africa, Zimbabwe &amp; US. Expected start 2023; will determine film to be used in first-in-human trial of monthly dapivirine film.</td>
</tr>
<tr>
<td>Cabotegravir hydrogel injectable</td>
<td>CONRAD (USA)</td>
<td>Injectable depot</td>
<td>Cabotegravir Integrase strand inhibitor (ARV)</td>
<td>Injection given under the skin</td>
<td>4-6 months</td>
<td>Initially a liquid, hydrogel forms into a small ball that would slowly release drug as it dissolves. (If needed, removable in first month) Also being developed as dual-purpose product</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Cabotegravir dissolvable pellets</td>
<td>CONRAD (USA)</td>
<td>Pellet implant</td>
<td>Cabotegravir Integrase strand inhibitor (ARV)</td>
<td>Inserted under skin</td>
<td>Up to 1 year</td>
<td>8-9 pellets would be inserted in a row that slowly release drug as they dissolve in course of a year. (If needed, removable in first 1-2 mos) Also being developed as dual-purpose product</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Product</td>
<td>Developer</td>
<td>Product Type</td>
<td>Active Ingredient(s)</td>
<td>How used</td>
<td>Protection Goal</td>
<td>Unique Features/ Additional Information</td>
<td>Development Status</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------------------</td>
<td>----------</td>
<td>----------------</td>
<td>------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>1</td>
<td>Non-ARV/ nonhormonal contraceptive dual-purpose vaginal ring</td>
<td>Oak Crest Inst of Science (USA)</td>
<td>Vaginal ring</td>
<td>Antiviral peptide (non-ARV) (protein fragment) Non-hormonal contraceptive A soluble Adenylate Cyclase (sAC) inhibitor; affects sperm’s ability to move, fertilize eggs</td>
<td>Women insert themselves</td>
<td>1-3 months</td>
<td>The antiviral also shows activity against HSV and HPV, which could be an added benefit.</td>
</tr>
<tr>
<td>2</td>
<td>Dapivirine and levonorgestrel vaginal film</td>
<td>Univ of Pittsburgh (USA)</td>
<td>Vaginal film</td>
<td>Dapivirine NNRTI (ARV) Levonorgestrel (LNG) hormonal contraceptive</td>
<td>Women insert themselves</td>
<td>1 month</td>
<td>As film slowly dissolves it would release both dapivirine and LNG until film completely dissolves</td>
</tr>
<tr>
<td>3</td>
<td>Cabotegravir/levonorgestrel hydrogel injectable</td>
<td>CONRAD (USA)</td>
<td>Injectable depot</td>
<td>Cabotegravir Integrase strand inhibitor (ARV) Levonorgestrel (LNG) hormonal contraceptive</td>
<td>Injection given under the skin</td>
<td>4-6 months</td>
<td>Initially a liquid, hydrogel forms into a small ball that would slowly release drug as it dissolves. (If needed, could be removed in first month)</td>
</tr>
<tr>
<td>4</td>
<td>Cabotegravir/levonorgestrel dissolvable pellets</td>
<td>CONRAD (USA)</td>
<td>Pellet implant</td>
<td>Cabotegravir Integrase strand inhibitor (ARV) Levonorgestrel (LNG) hormonal contraceptive</td>
<td>Inserted under skin</td>
<td>Up to 1 year</td>
<td>8-9 pellets would be inserted in a row that slowly release drug as they dissolve in course of a year. (If needed, could be removed in first 1-2 mos)</td>
</tr>
</tbody>
</table>
Meet the TAF/EVG Insert

"The Weekend Special"

A dual-compartment (vaginal/rectal) insert for flexible, user-controlled, on-demand HIV prophylaxis

+ For all sexually-active ages and genders, especially AGYW
+ Highly discreet and portable
+ Low systemic exposure → drug where and when you need it
+ Designed to be used on-demand pre- or post-coitus
+ Provides potential added benefit of HSV prophylaxis

Under MATRIX, product development focused on vaginal use for primary indication of HIV prevention

Through other/future funding would be pursuing rectal use and prevention against HSV-2 and other STIs
Why TAF/EVG Inserts?

How is it different from existing/approved PrEP products?

- No other user-controlled, on-demand HIV prevention product in clinical trials
- Provides new event-driven PrEP option for women (ED oral PrEP currently approved for MSM only)
- Fewer doses and side effects expected than oral/systemic PrEP
- Potential for additional protection against HSV-2 acquisition and dual compartment (vaginal/rectal) use
- Most advanced product in MATRIX’s current product portfolio, with:
  - Preclinical proof-of-concept in non-human primates
  - Clinical proof-of-concept (CONRAD-146, MTN-039)
  - User acceptability & ease-of-use demonstrated
- Simple manufacturing = readily affordable, scalable, deliverable
MATRIX-001: Overview

- Phase I study: Evaluate safety of the TAF/EVG (NRTI/integrase inhibitor) fast-dissolving insert (FDI) used vaginally
  - Will also evaluate user acceptability, how and where the two drugs are taken up in the body, and potential activity against HIV and herpes simplex virus (HSV)
- Will enroll 60 women at 3 trial sites
- The first study of the TAF/EVG fast-dissolving insert in African women. Study to open in October 2023
- **Dosing**: daily for 3 days, then every other day for 14 days
Why MATRIX-001?

• Researchers need to know about **the safety** of the TAF-EVG insert with more frequent vaginal use (not just one time)

• Need to understand **safety and acceptability in African women**, not just women in the US

• Will provide information about **where the drugs go in the body**—and **how long they remain there**—when used consecutive days as a vaginal insert, as well as insight into the product’s **potential effectiveness** against HIV and HSV

• Study results will determine **whether the TAF/EVG insert should proceed to Phase 2 studies** to evaluate its safety and acceptability when used as designed—at or around the time of sex, and vaginally
Why Vaginal films?

**Ease of Use & Privacy:**
Women control use and insertion of film
Can be used discreetly and inserted anytime in private
Not expected to impact sex

**Unique & Convenient Platform:**
Removal not required
Complete drug release
Small and portable

**Low Cost:**
Inexpensive to manufacture
No applicator required

**Safe with No Messiness:**
Minimal impact on vaginal health
Minimal to no additional vaginal discharge
How would the film work?

Film is wetted by and mixes with vaginal fluids.

As the film slowly dissolves, dapivirine would spread throughout the vagina.

1-month use

Dapivirine

After 30 days, the film would be completely dissolved.

MATRIX
MATRIX-002 Overview

- Trial to assess acceptability, usability and safety of two placebo prototype vaginal films which differ in shape

- To be conducted at five clinical sites (MWRI, KEMRI, Aurum, Wits RHI, HHRC)
  - 100 participants (18-45 y/o) and up to 30 sexual partners
  - No sexual activity or product use in 1st month, no restrictions in 2nd month. Study to launch in October 2023

- Key questions to be addressed:
  - Do women like the vaginal film?
  - Which film shape is better?
  - Can women insert the vaginal films themselves?
  - What do sexual partners think about the film?
  - Will sex or vaginal products/practice interfere with film use?
Why MATRIX-002?

The concept of a vaginal film is unfamiliar to many women – perhaps especially, African women. The idea of a monthly vaginal film is brand new.

- Quick-dissolve vaginal films and a 7-day film have been evaluated in US women.
- In the QUATRO study, women in South Africa and Zimbabwe tried a quick-dissolve placebo film.

Before evaluating the monthly dapivirine film in a first-in-human Phase 1 study:

- Researchers need to know that women will be comfortable with the idea of using a monthly film and are able to insert it.
- They also want to be sure that the “right” film is the one that moves forward: which of the two films do women find easier to use? Which is safest?
OneRing – An Innovative Dual-purpose Prevention Product

Highlights of activities to date:

- Antiviral agent (peptide) formulation development
- Contraceptive agent formulation development
- Bioanalytical method development
- Safety and pharmacokinetics in sheep
- Antiviral activity studies in mice
- Ring design and formulation
- Regulatory
- Studies to support regulatory
**MATRIX-003**

- **MATRIX-003** will gather acceptability, usability, and safety data of 2 placebo prototypes of a new type of ring (OCIS OneRing) which differ in firmness.
- The rings’ size is similar to that of approved devices and multiple clinical trials (like the dapivirine vaginal ring), but the design is different as it includes two cassettes (cartridges).
- Designed for simultaneous delivery of two medications (non-ARV antiviral and non-hormonal contraceptive) for HIV and pregnancy prevention.
- Each participant will use each ring for ~28 days - allow assessment of ring use and preference for the different rings (without the impact of drug related side effects).
MATRIX-003

- This data collected in **MATRIX-003** will guide the final design of a dual-purpose vaginal ring that
  - Contains non-ARV and non-hormonal drugs that act locally – fewer side effects, less concern about viral resistance, rapid return to fertility
  - Could offer long-term protection from both pregnancy and HIV (30 days)
  - Women can use discretely and insert and remove themselves
  - Goal is low cost and easy to manufacture
MATRIX Products Not Yet in Trials

- Cabotegravir implantable pellets (with and without LNG)
- Cabotegravir depot injectable (with and without LNG)
- Griffithsin Fast dissolving insert
This program was made possible by the generous support of the American people through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID).

The contents in this presentation are those of the presenter and do not necessarily reflect the view of the U.S. President’s Emergency Plan for AIDS Relief, the U.S. Agency for International Development or the U.S. Government.
Additional Slides to be used if necessary
CAB Bioresorbable Pellets and Hydrogel Injectable in Development by CONRAD

For users of all ages and genders

Administered under the skin by healthcare provider similar to contraceptives

Option for 2-in-1 Dual Purpose Product with added contraceptive to meet needs of more users

Reduce clinic visits, costs, time, monitoring efforts

Longer duration (~6-12 months)

CAB Hydrogel Injectable

CAB Pellets

For users of all ages and genders

Option for 2-in-1 Dual Purpose Product with added contraceptive to meet needs of more users

Reduce clinic visits, costs, time, monitoring efforts

Longer duration (~6-12 months)
CAB Pellet Attributes

- Small (3x5-10mm) cylindric solid dosage form; GRAS excipients
- High CAB drug loading of up to 90% per pellet; supports longer duration
- Scalable, affordable, stable; no cold-chain storage required
- Controlled release; supports long-term PK profile
- Bioresorbable; no need for removal, CAB and LNG have good safety profiles
- User-friendly insertion; administrable with commercial trocar, but designed for ultimate delivery in pre-loaded, HCD inserter

Target: protective plasma levels for 9-12 months (CAB only) and 6-12 months (CAB/LNG)
How would CAB & CAB/LNG Pellets be inserted?

Ultimately, pellets would be preloaded in sterile HCD inserter*

While the user is seated, the pellets would be implanted under the skin by clinic provider with inserter

Pellets would release CAB or CAB/LNG (in dual purpose product) immediately and for 6-12 months

Pellets fully dissolve

Return to clinic for next implanted dose

* Development funded under Project NIX HIV & UChoose
CAB and CAB/LNG Hydrogel Injectable

- Uses a hydrogel drug delivery technology that is:
  - Made of natural ingredients (silica and water)
  - Shear thinning, so may be injected either under skin (SC) or into muscle (IM) using a small needle
  - Forms a bubble-like “depot” where injected that slowly degrades (dissolves) over time
  - As it dissolves, the drug payload is slowly released and absorbed into bloodstream
  - 6-month target duration for protection
Why and What is Griffithsin (GRFT)?

- Non-ARV with broad antiviral properties
- Protein discovered in algae — now bioengineered
- Promising preclinical and early clinical data
- Highly potent against HIV — effective at sub-nanomolar concentrations
- Topically-active/non-systemic
Why Fast-dissolving Insert (FDI)?

User Acceptance
- Endorsed as highly desired by end-users
- Discreet, easy to use, portable
- Anticipate minimal impact on vaginal discharge → lower risk of partner detection

Product Characteristics
- Relatively simple manufacturing and capacity to scale-up production
- Optimal for wide distribution
Our Product

- Quick onset (<20 minutes)
- **12+** hours duration of protection
- Portable, stable at room temperature
- No inserter
  - Discreet placement with finger
  - Reduced waste/cost
- Could possibly use with other prevention methods
- Manufacturing of GRFT being optimized for possible phase 1 in 2024